Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Rare Disease Genetic Testing Industry?
The market size of genetic testing for rare diseases has seen swift expansion in the past few years. Projected growth points towards a rise from $1.03 billion in 2024 to $1.17 billion in 2025, with a compound annual growth rate (CAGR) of 13.6%. Factors contributing to this increase during the historical period include growing consciousness about rare genetic diseases, an escalating demand for timely and precise diagnosis, growth in governmental funding for researching rare ailments, expanded access to genetic testing services, an upsurge in investments in precision medicine, and a surge in the prevalence of uncommon genetic conditions.
In the coming years, the market size for genetic testing for rare diseases is predicted to experience substantial growth, reaching $1.93 billion by 2029 with a compound annual growth rate (CAGR) of 13.3%. This growth in the projected timeline is credited to the rising implementation of next-generation sequencing, heightened focus on tailored medical treatments, increased funding for genetic research, improved healthcare facilities in developing markets, a growing prevalence of diagnostic testing, an upsurge in genetic cancer screening, and the burgeoning demand for non-invasive diagnostic procedures. Key trends during this projection period will include advancements in genome editing technology, sophisticated bioinformatics tools for the analysis of genetic data, progress in multi-gene panel tests, developments in portable genetic testing equipment, and novel techniques for sample collection.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp
#Which Factors Are Currently Driving The Growth Of The Rare Disease Genetic Testing Market?
The rise in genetic disorders is anticipated to fuel the expansion of the rare disease genetic testing market in the future. Genetic disorders are medical conditions that result from abnormalities in a person’s DNA, which can be inherited from both or one parent, or due to new mutations. The upswing in genetic disorders can be linked to an increase in parental age, since older parents are more likely to pass on genetic mutations to their offspring. Rare disease genetic testing aids in identifying these specific mutations, facilitating the accurate and early diagnosis of genetic disorders. It allows for tailored treatments, thereby improving patient care and long-term health outcomes. As per the data shared by the National Health Service, a government department based in the UK, in May 2024, about 17,000 people are living with sickle cell disease, a hereditary genetic blood disorder with approximately 250 new cases diagnosed each year. Hence, the burgeoning genetic disorders are steering the growth of the rare disease genetic testing market.
How Is The Global Rare Disease Genetic Testing Market Structured In Terms Of Segments?
The rare disease genetic testing market covered in this report is segmented
1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types
2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies
3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests
4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users
Subsegments:
1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders
2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension
3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders
4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions
5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders
6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders
7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions
What Trends Are Currently Influencing Growth In The Rare Disease Genetic Testing Market?
The focus of key players in the rare disease genetic testing market has been on creating superior tech-powered solutions such as digital genomics platforms. These platforms aim to increase the efficiency, reliability and scalability of diagnosing rare diseases. Digital genomics platforms are technologically advanced software systems that combine genomic data analysis, insight, and reporting to simplify and hasten the process of genetic testing and diagnosis. Strand Life Sciences Private Limited, headquartered in India and specializing in computer software, for example, initiated their digital platform StrandOmics Portal in March 2025. This platform is designed to improve efficiency and precision in rare disease diagnosis by providing clinicians with comprehensive insights into genetic variants, thereby allowing for faster, more accurate diagnoses. The platform also allows genetic data reviews to be done independently and supports sophisticated variant interpretation, including prenatal diagnostics. This introduction highlights the strong dedication to improve precision medicine and arm healthcare professionals with effective resources to boost patient results.
Who Are The Main Participants Shaping The Rare Disease Genetic Testing Market Landscape?
Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Realm IDX Inc., Artemis DNA Inc., BGI Genomics Co. Ltd.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report
Which Region Currently Holds The Largest Share In The Rare Disease Genetic Testing Market?
North America was the largest region in the rare disease genetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27404&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model